Comparison of Different Promoter Methylation Assays in Breast Cancer
Background: Promoter hypermethylation has emerged as a promising cancer biomarker. Currently, a large variety of quantitative and non-quantitative techniques is used to measure methylation in clinical specimens. Here we directly compared three commonly used methylation assays and assessed the influe...
Main Authors: | Karijn P. M. Suijkerbuijk, Xiaojuan Pan, Elsken van der Wall, Paul J. van Diest, Marc Vooijs |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2010-01-01
|
Series: | Analytical Cellular Pathology |
Online Access: | http://dx.doi.org/10.3233/ACP-CLO-2010-0542 |
Similar Items
-
Low Levels of BNIP3 Promoter Hypermethylation in Invasive Breast Cancer
by: Paul J. van Diest, et al.
Published: (2010-01-01) -
Conditional Inactivation of HIF-1 Using Intrabodies
by: Arjan J. Groot, et al.
Published: (2008-01-01) -
Primary prevention of breast cancer in high-risk women by monitoring epigenetic changes in nipple aspirates
by: van Diest PJ, et al.
Published: (2009-07-01) -
COMMD1 Promotes pVHL and O2-Independent Proteolysis of HIF-1alpha via HSP90/70.
by: Bart van de Sluis, et al.
Published: (2009-10-01) -
Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls
by: van der Wall Elsken, et al.
Published: (2010-04-01)